Recognized for delivering AI-simulated roleplay tailored to the unique needs of the Life Sciences industry
TORONTO and NEW YORK–May 15, 2026 — ACTO, uniting human intelligence with empathetic AI in Life Sciences, today announced that it has been named a winner of the 2026 Evan Kirstel’s We Love Tech Awards, an annual program celebrating the individuals, organizations, and products reshaping how enterprises work, communicate, secure data, serve customers, and put artificial intelligence into responsible production.
CxZone by ACTO is the first and only AI-simulated role-play solution exclusively designed for pharmaceutical field professionals. CxZone was built to help sales reps and MSLs elevate the HCP experience by mastering clinical conversations in a fast, flexible, and feedback-rich environment designed for the unique complexities of the Life Sciences industry.
“We built CxZone to reflect the real conversations field teams have every day, not generic simulations,” said Parth Khanna, CEO of ACTO. “Our goal is to bring the same speed we’re seeing in AI-driven drug development to the post-approval phase, giving field teams a place to practice, improve, and spend more time in meaningful engagement with HCPs. This recognition reinforces the role of focused, industry-specific AI in helping teams show up better in the moments that matter.”
With CxZone, reps can practice personalized conversations in a safe space. ACTO has seen the following results from AI-simulated role-play:
- An 85% increase in field team confidence
- A 2x increase in field team scientific knowledge
- A 71% increase in field rep engagement in practice
“CxZone is a great example of what happens when an AI product is built for a single, specific industry instead of trying to be everything to everyone,” said Evan Kirstel, Founder, We Love Tech Awards. “Pharmaceutical field teams now have a simulated, feedback-rich environment to master clinical conversations, and that vertical specificity is precisely what makes this product stand out.”
The 2026 We Love Tech Awards recognize honorees across Individual, Organization, and Product nomination types in 15 solution categories spanning artificial intelligence, cloud computing, customer experience, cybersecurity, SaaS, IoT, and more. Almost 400 volunteer judges evaluated entries using the program’s domain-specific scoring framework. The full list of 2026 winners is available at welovetechawards.com.
About ACTO
Trusted by 14 of the top 50 pharmaceutical companies, high-growth biotechs, and leading medtech organizations, ACTO is redefining how therapies reach patients after regulatory approval. We unite human intelligence with empathetic AI through our AI-powered Field Excellence Platform and AI SuperAgents to accelerate product launches, strengthen field execution, and deepen customer engagement. By elevating training and coaching while agentifying up to 30% of the work embedded in customer-facing roles, ACTO frees teams to focus on what matters most: human connection, judgment, and strategic execution. Built to meet the industry’s highest regulatory standards, ACTO is FDA 21 CFR Part 11 validated and SOC 2 Type II certified. Learn more at www.acto.com.
About Evan Kirstel
Evan Kirstel is one of the most influential voices in B2B technology, with a social reach of more than 550,000 followers across his podcast, YouTube, LinkedIn, X, and Instagram. With years of experience working with Fortune 1000 brands, Evan helps companies harness social media for strategic growth, audience engagement, and social selling. Learn more at evankirstel.com.
About Business Intelligence Group
Business Intelligence Group (BIG) is an independent awards organization that has been recognizing outstanding achievement in business since 2012. Now in its 14th awards season, BIG operates more than 10 annual programs spanning innovation, artificial intelligence, cybersecurity, customer service, cloud computing, sustainability, sales and marketing, workplace culture, and women’s leadership.uilt to meet the industry’s highest regulatory standards, ACTO is FDA 21 CFR Part 11 validated and SOC 2 Type II certified. Learn more at www.acto.com.